Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995898 · ClinicalTrials.gov registry record · NA
The Vanguard Study: Testing a New Way to Screen for Cancer
A NA study of Malignant Solid Neoplasm and Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- NA
- Development phase
- 24,000
- Enrollment target
- 20
- Study locations
NCT06995898 is a NA study of Malignant Solid Neoplasm and Breast Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 24,000 participants, above the 1,004-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (2290% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06995898, a NA study of Malignant Solid Neoplasm and Breast Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- NA
- Development phase
- 24,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
- DEVICE Device Usage
- PROCEDURE Multi-Cancer Detection Test
Study Locations (20)
Michigan
- Henry Ford Cancer Institute-Downriver - Brownstown
- Henry Ford Health Center - Brownstown - Brownstown
- Henry Ford Health Center - Chesterfield - Chesterfield
- Henry Ford Macomb Hospital-Clinton Township - Clinton Township
- Henry Ford Medical Center-Fairlane - Dearborn
- Henry Ford Hospital - Detroit
- Henry Ford Medical Center - Detroit Northwest - Detroit
- Henry Ford Medical Center-Cottage - Grosse Pointe Farms
- Henry Ford Medical Center - Livonia - Livonia
- Henry Ford Medical Center-Columbus - Novi
Colorado
- Keefe Memorial Hospital - Cheyenne Wells
- Kaiser Permanente-Franklin - Denver
- Poudre Valley Hospital - Fort Collins
- Cancer Care and Hematology-Fort Collins - Fort Collins
- UCHealth Greeley Hospital - Greeley
- Kaiser Permanente-Rock Creek - Lafayette
- Kaiser Permanente-Lone Tree - Lone Tree
- Medical Center of the Rockies - Loveland
California
- Kaiser Permanente-Division of Research - Pleasanton
Hawaii
- Kaiser Permanente Moanalua Medical Center - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24,000 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995898
The ClinicalTrials.gov registry entry for NCT06995898 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,004-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (2290% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06995898 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT06995898 about?
NCT06995898 is a clinical study titled "The Vanguard Study: Testing a New Way to Screen for Cancer". The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand ho...
What is the current status of trial NCT06995898?
This trial is currently recruiting. It is a NA study. The enrollment target is 24,000 participants. The study started on 2025-06-16. Estimated completion is 2029-06-30.
What conditions does trial NCT06995898 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Ovarian Carcinoma.
What interventions are being tested in trial NCT06995898?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER), Device Usage (DEVICE), Multi-Cancer Detection Test (PROCEDURE).
Who is sponsoring clinical trial NCT06995898?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995898 being conducted?
This trial has 20 study locations across California, Colorado, Hawaii, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Genetic Testing for the Prevention of Cancer in Indigenous American Communities (JUNIPER Trial)
RECRUITING · NA
-
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
RECRUITING · NA
-
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
RECRUITING · NA
-
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
RECRUITING · NA
-
Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.